⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL366182 | 1.00 | — | — | |
| Water SCHEMBL7290181 | 0.94 | — | — | |
| Water SCHEMBL7315178 | 0.94 | — | — | |
| Hydrochloric Acid SCHEMBL9808559 | 0.94 | — | — | |
| SCHEMBL6651200 | 0.94 | — | — | |
| SCHEMBL2121176 | 0.94 | — | — | |
| Hydroxyamine SCHEMBL10528078 | 0.88 | — | — | |
| Boric Acid SCHEMBL28199347 | 0.86 | — | — | |
| SCHEMBL28100509 | 0.85 | — | — | |
| Bicarbonate SCHEMBL8820662 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2995 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345401-A1 | TOPICAL THERAPEUTIC FORMULATIONS | HYBRID MEDICAL, LLC | 2025-11-13 | — | — | US | claimed |
| WO-2025224756-A1 | COMPOSITION, METHOD AND USE THEREOF FOR DELAYING PRIMARY TUMOR METASTASIS USING AMLODIPINE | MESTASTOP SOLUTIONS PRIVATE LIMITED (IN) | 2025-10-30 | — | — | WO | claimed |
| EP-4565230-A1 | METHODS FOR TREATING OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY | Cytokinetics, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| US-12290552-B2 | Topical therapeutic formulations | Hybrid Medical, Inc. (US) | 2025-05-06 | — | — | US | claimed |
| CN-119907668-A | Methods for treating obstructive hypertrophic cardiomyopathy | 赛特凯恩蒂克公司 | 2025-04-29 | — | — | CN | claimed |
| US-20250084388-A1 | ALK4:ACTRIIB HETEROMULTIMERS AND USES THEREOF | ACCELERON PHARMA INC (US) | 2025-03-13 | — | — | US | claimed |
| CN-119446511-A | Prognosis evaluation method and device for primary aldosteronism patient | 上海交通大学医学院附属瑞金医院 | 2025-02-14 | — | — | CN | claimed |
| US-20240315956-A1 | METHOD OF PRODUCTION OF THE COMPOSITION OF CYCLOOXYGENASE-2 (COX-2) INHIBITORS | US Nano Food & Drug INC | 2024-09-26 | — | — | US | claimed |
| US-20240316085-A1 | METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES | Tulavi Therapeutics, Inc. | 2024-09-26 | — | — | US | claimed |
| EP-4398892-A1 | CARDIAC ORGANOID AND ANTI-ELECTRO-MITOCHONDRIAL DESYNCHRONIZATION THERAPY | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2024-07-17 | — | — | EP | claimed |
| EP-0680759-A1 | Transdermal delivery of calcium channel blockers, such as nifedipine | THE BOARD OF GOVERNORS FOR HIGHER EDUCATION STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS (US) | 1995-11-08 | — | — | EP | claimed |
| US-5457132-A | Comprising a hypotensive agent and a calcium compound; synergistic, side effect reduction, enzyme inhibitor | Pang, Peter K. T. (CA) | 1995-10-10 | — | — | US | claimed |
| US-5439687-A | Having homogeneous matrix containing hydroxypropyl methyl cellulose, calcium antagonist, excipients | SIEGFRIED PHARMA AG (CH) | 1995-08-08 | — | — | US | claimed |
| US-5354765-A | Synergistic | Pang, Peter K. T. | 1994-10-11 | — | — | US | claimed |
| US-5209933-A | A dihydropyridine compound | SYNTEX (U.S.A.) INC. (US) | 1993-05-11 | — | — | US | claimed |
| EP-0231026-B1 | SUSTAINED-RELEASE DIHYDROPYRIDINE FORMULATION | SYNTEX (U.S.A.) INC. (US) | 1992-11-04 | — | — | EP | claimed |
| US-5124340-A | Use of calcium channel blocker to prevent cocaine induced craving and reinforcement | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1992-06-23 | — | — | US | claimed |
| US-4940556-A | SUSTAINED RELEASE OF CALCIUM CHANNEL BLOCKERS | SYNTEX (U.S.A.) INC. (US) | 1990-07-10 | — | — | US | claimed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| EP-0231026-A1 | Sustained-release dihydropyridine formulation | SYNTEX (U.S.A.) INC. (US) | 1987-08-05 | — | — | EP | claimed |